Analysts at InCred Equities said they are disappointed with the repeated delay in Cenexi's turnaround and will reassess the ...

Generic injectables maker Gland Pharma on February 3 reported a 7% rise in third-quarter profit, as lower expenses helped ...

Quarterly Net Profit at Rs. 204.69 crore in December 2024 up 6.69% from Rs. 191.86 crore in December 2023. EBITDA stands at ...

Revenue from operations fell 10% year-on-year to Rs 1,384 crore. EBITDA increased by 1% year-on-year to Rs 360 crore, with ...

The EBITDA margin stood at 26% in the reporting quarter versus 23.1% YoY. The results came after the close of the market ...

Gland Pharma's consolidated net profit increased 6.67% to Rs 204.70 crore despite 10.42% decline in revenue from operations to Rs 1,384.1 crore in Q3 FY25 over Q3 FY25.

The thyroid gland at the base of the neck secretes an essential hormone crucial for development and metabolism. Both hypothyroidism and hyperthyroidis ...

Gland Pharma reported another disappointing quarter with weak revenue growth in its base business. Additionally, Gland Pharma ...

Indian generic injectables maker Gland Pharma reported a 7% rise in third-quarter profit on Monday, as lower expenses helped mitigate the impact from production issues at its French unit Cenexi.

Today, companies including Religare Enterprises, Gland Pharma, Fortis Malar Hospitals, Aditya Birla Capital, Alembic Pharma, ...

Garden Reach Shipbuilders Engineers (GRSE) reported 11% year-on-year (YoY) growth in its net profit at Rs 98 crore for the ...